The following is just a small sampling of recent Neurovascular market updates from around the world compiled, reviewed and posted daily by our SmartTRAK analysts.
New Products:
Imperative Care announced the completion of first cases using the recently FDA-cleared Zoom 88 Support catheter. One of the cases was an AIS patient with a tandem occlusion treated at Erlanger Health System in Chattanooga, TN. SmartTRAK reported FDA clearance of the device on Jun 15.
EOSolutions announced the full commercial launch of its Dr. Banner, Balloon Guide Catheter (BGC), developed in collaboration with InNeuroCo. According to the Company, the BGC features a 0.091 ID, proximal stability, distal trackability and a compliant polyurethane balloon.
Patents:
phenox GmbH’s US Patent Application “Insertion System For Implants For Treatment Of Bifurcation Aneurysms” was published disclosing a Y-shaped tubular implant and Y-shaped insertion catheter for bifurcation aneurysm treatment. 20230233347
The Univ of Toledo’s US Patent Application “Aspiration Catheter With An Adjustable Tip For The Intracranial Circulation” was published disclosing a neurovascular aspiration catheter with an adjustable tip controlled by pull wires. 20230233221
Hangzhou ArteryFlow Technology’s US Patent Application “Microcatheter Path Generation Method, Shaping Method Of Mandrel, Computer Equipment, Readable Storage Medium And Program Product” was published re a vascular model to find a path from a starting point to an ICA. 20230210600
Studies:
Route 92
A 36-patient 2-year single-center experience with Route 92’s triaxial catheter assembly and HiPoint 0.088” LBC reported* 26 patients were treated with the 0.088” LBC alone. Single pass mTICI 2C/3 was achieved in 22 cases, and all patients had mTICI ≥ 2B. SNIS 2023 E-poster
JNJ/DePuy Synthes*
A CERENOVUS-supported E-poster presented* the results of a Delphi method consensus from the 2022 CLOTS 7.0 Summit that describes what a challenging clot could be and suggests technique should be switched after 3 failed MT passes. SNIS 2023 E-poster
Deals/Financing:
RapidAI announced $75MM in Series C funding led by Vista Credit Partners. The funding aims to drive platform innovation to support more disease states and go-to-market functions to accelerate growth in new regions and product verticals.
Clinical/Regulatory:
A 150-patient clinical trial in Vietnam in collaboration with Acandis GmbH will assess the use of the Credo stent in the treatment of symptomatic intracranial stenosis based on rates of stroke at death and 1-with f/up. Estimated study completion is Oct 2024. clinicaltrials.gov
Two vs One Stent Retriever for AIS Thrombectomy
A 200-patient clinical trial will compare the effectiveness and safety of the use of 2 SRs simultaneously vs one SR as a first-choice treatment for AIS thrombectomies. Est study completion is July 2024. clinicaltrials.gov
Markets:
Due to research on MT in other AIS patients (e.g., low ASPECTS, late time window, posterior circulation, etc.), the number of US AIS patients who are potential MT candidates is projected to increase from ~247,140 in 2022 to ~258,909 in 2027E. SmartTRAK Mechanical Thrombectomy Market Overview*
Revenues:
For Q4FY23, MDT’s Specialty Therapies saw broad-based strength on LDD growth in NV and ENT and MSD growth in Pelvic Health. MDT Q4FY23 Earnings Release AXNX Q223 Earnings Release
In 2022, MicroPort’s overseas neurovascular revenue surpassed $3MM for the first time, with revenue mainly coming from the US, Korea and Europe. MicroPort Scientific 2022 Annual Report
Penumbra*
PEN increased its guidance for FY23 to be in the range of $1.04B to $1.06B, representing +23% to +25% growth over FY22 revenue of $847.1MM. PEN expects vascular biz growth to be slightly above this range and neuro biz growth to be below this range. PEN Q123 Earnings Release
* These links can only be viewed by SmartTRAK subscribers. For more information on SmartTRAK, including how to receive a demo and subscribe, please click here.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.